NBI與AMEX生技指數各漲7.76%、5.78%,NYSE藥業指數漲5.66%。
國際藥廠動態
本週,Nektar的主要候選藥物bempegaldesleukin,聯合必治妥施貴寶的Opdivo,用於治療黑色素瘤的三期試驗宣告失敗。
莫德納的mRNA 愛滋病疫苗收治首位病患並完成給藥。
2022年03月-美股7日漲跌幅排名(0311-0318) |
|||||
| 個股代碼 | 名稱 | 本周收價(美元) | 上周收價(美元) | 漲跌幅 | 備註 |
| IBB | iShares Biotechnology ETF | 130.99 | 120.65 | 8.57% | |
| #NBI | NASDAQ生物科技指數 | 4173.39 | 3872.89 | 7.76% | |
| #BTK | AMEX生物科技指數 | 5085.5 | 4807.7 | 5.78% | |
| 個股代碼 | 名稱 | 本周收價(美元) | 上周收價(美元) | 漲跌幅 | 分類 |
| EDIT | Editas Medicine | 18.36 | 15.06 | 21.91% | 基因編輯 |
| NTLA | Intellia Therapeutics | 72.33 | 61.29 | 18.01% | 基因編輯 |
| BLUE | bluebird bio | 4.99 | 4.38 | 13.93% | 生技:CART |
| ILMN | Illumina | 346.11 | 303.87 | 13.90% | 生技:醫材 |
| MACK | Merrimack Pharmaceuticals | 6.74 | 6.06 | 11.22% | 台灣授權 |
| CRSP | CRISPR Therapeutics AG | 67.89 | 61.42 | 10.53% | 基因編輯 |
| PFE | Pfizer | 54.51 | 50.27 | 8.43% | 製藥 |
| LLY | Eli Lilly and | 287.64 | 266.3 | 8.01% | 製藥 |
| ABT | Abbott Laboratories | 122.45 | 114.02 | 7.39% | 製藥 |
| ABBV | AbbVie | 159.2 | 149.06 | 6.80% | 製藥 |
| REGN | Regeneron Pharmaceuticals | 685.94 | 642.58 | 6.75% | 製藥 |
| CI | Cigna | 241.16 | 226.86 | 6.30% | 醫療保健 |
| GSK | GlaxoSmithKline PLC | 43.02 | 40.56 | 6.07% | 製藥 |
| BIIB | Biogen | 208.57 | 197.67 | 5.51% | 生技 |
| TEVA | Teva Pharmaceutical Industries | 7.89 | 7.48 | 5.48% | 製藥 |
| NVS | Novartis AG | 86.79 | 82.37 | 5.37% | 製藥 |
| CLVS | Clovis Oncology | 1.66 | 1.58 | 5.06% | 製藥:PARP |
| AZN | AstraZeneca PLC | 63.23 | 60.3 | 4.86% | 製藥 |
| JNJ | Johnson & Johnson | 174.84 | 169.35 | 3.24% | 製藥 |
| AMGN | Amgen | 236.25 | 228.85 | 3.23% | 生技 |
| BMY | Bristol-Myers Squibb | 71.02 | 68.87 | 3.12% | 製藥:PD-1 |
| SNY | Sanofi | 52.09 | 50.71 | 2.72% | 製藥 |
| GILD | Gilead Sciences | 59.42 | 58 | 2.45% | 生技 |
| MRK | Merck | 79.11 | 78.26 | 1.09% | 製藥:PD-1 |
| ASLN | ASLAN Pharmaceuticals | 0.7936 | 0.8 | -0.80% | 製藥(臺美雙掛牌) |
| AKBA | Akebia Therapeutics | 2.5 | 2.61 | -4.21% | 製藥(併KERX) |
| CLLS | Cellectis S.A. | 4.06 | 4.4 | -7.73% | 生技:CART |